Clinical Epigenetics · 2015 · 119 citations · 41 references
MedicineCancer BiologyMolecular BiologyEpigeneticsGene ExpressionMolecular OncologyCancer EpigeneticsEpigenetic Alterations In CancerEpigenetic Regulation In CancerMolecular Tumor ProfilingPolycomb RegulationProstate CancerEpigenetic DysregulationGenome-wide Epigenetic ProfilingPolycomb Group ProteinsPolycomb Group RegulationPolycomb Group RepressionPolycomb-mediated SilencingTranscriptional Regulation GenesTranscriptional Repressors
BACKGROUND: Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PCa) for which the median survival remains less than a year. Current treatments are only palliative in nature, and the lack of suitable pre-clinical models has hampered previous efforts to develop novel therapeutic strategies. Addressing this need, we have recently established the first in vivo model of complete neuroendocrine transdifferentiation using patient-derived xenografts. Few genetic differences were observed between parental PCa and relapsed NEPC, suggesting that NEPC likely results from alterations that are epigenetic in nature. Thus, we sought to identify targetable epigenetic regulators whose expression was elevated in NEPC using genome-wide profiling of patient-derived xenografts and clinical samples. RESULTS: Our data indicate that multiple members of the polycomb group (PcG) family of transcriptional repressors were selectively upregulated in NEPC. Notably, CBX2 and EZH2 were consistently the most highly overexpressed epigenetic regulators across multiple datasets from clinical and xenograft tumor tissues. Given the striking upregulation of PcG genes and other transcriptional repressors, we derived a 185-gene list termed 'neuroendocrine-associated repression signature' (NEARS) by overlapping transcripts downregulated across multiple in vivo NEPC models. In line with the striking upregulation of PcG family members, NEARS was preferentially enriched with PcG target genes, suggesting a driving role for PcG silencing in NEPC. Importantly, NEARS was significantly associated with high-grade tumors, metastatic progression, and poor outcome in multiple clinical datasets, consistent with extensive literature linking PcG genes and aggressive disease progression. CONCLUSIONS: We have explored the epigenetic landscape of NEPC and provided evidence of increased PcG-mediated silencing associated with aberrant transcriptional regulation of key differentiation genes. Our results position CBX2 and EZH2 as potential therapeutic targets in NEPC, providing opportunities to explore novel strategies aimed at reversing epigenetic alterations driving this lethal disease.
41
Min Xiu, Juanjuan Xing, Shaoqing Yu et al. · Cellular Physiology and Biochemistry · 2017 · 5.8K citations · Full text
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Daniel R. Rhodes, Jianjun Yu, K. Shanker et al. · Neoplasia · 2004 · 3.7K citations · Full text
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina, Ping Yang, Stephen D. Cassivi et al. · Mayo Clinic Proceedings · 2008 · 2.9K citations